These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19508175)

  • 1. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.
    Caraglia M; Marra M; Tagliaferri P; Lamberts SW; Zappavigna S; Misso G; Cavagnini F; Facchini G; Abbruzzese A; Hofland LJ; Vitale G
    Curr Cancer Drug Targets; 2009 Aug; 9(5):690-704. PubMed ID: 19508175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferons: ancient peptides with still under-discovered anti-cancer properties.
    Caraglia M; Dicitore A; Marra M; Castiglioni S; Persani L; Sperlongano P; Tagliaferri P; Abbruzzese A; Vitale G
    Protein Pept Lett; 2013 Apr; 20(4):412-23. PubMed ID: 23016588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balance between IL-3 and type Iinterferons and their interrelationship with FasL dictates lifespan and effector functions of human basophils.
    Hagmann BR; Odermatt A; Kaufmann T; Dahinden CA; Fux M
    Clin Exp Allergy; 2017 Jan; 47(1):71-84. PubMed ID: 27910206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.
    Caraglia M; Marra M; Viscomi C; D'Alessandro AM; Budillon A; Meo G; Arra C; Barbieri A; Rapp UR; Baldi A; Tassone P; Venuta S; Abbruzzese A; Tagliaferri P
    Int J Cancer; 2007 Nov; 121(10):2317-30. PubMed ID: 17657738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells.
    Naviglio S; Spina A; Marra M; Sorrentino A; Chiosi E; Romano M; Improta S; Budillon A; Illiano G; Abbruzzese A; Caraglia M
    J Interferon Cytokine Res; 2007 Feb; 27(2):129-36. PubMed ID: 17316140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
    Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential gene induction by type I and type II interferons and their combination.
    Sanda C; Weitzel P; Tsukahara T; Schaley J; Edenberg HJ; Stephens MA; McClintick JN; Blatt LM; Li L; Brodsky L; Taylor MW
    J Interferon Cytokine Res; 2006 Jul; 26(7):462-72. PubMed ID: 16800785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-interferon and its effects on signalling pathways within cells.
    Caraglia M; Vitale G; Marra M; Budillon A; Tagliaferri P; Abbruzzese A
    Curr Protein Pept Sci; 2004 Dec; 5(6):475-85. PubMed ID: 15581417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.
    Müller E; Speth M; Christopoulos PF; Lunde A; Avdagic A; Øynebråten I; Corthay A
    Front Immunol; 2018; 9():2520. PubMed ID: 30450098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.
    Tagliaferri P; Caraglia M; Budillon A; Marra M; Vitale G; Viscomi C; Masciari S; Tassone P; Abbruzzese A; Venuta S
    Cancer Immunol Immunother; 2005 Jan; 54(1):1-10. PubMed ID: 15693134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative signaling pathways regulating type I interferon-induced apoptosis.
    Pokrovskaja K; Panaretakis T; Grandér D
    J Interferon Cytokine Res; 2005 Dec; 25(12):799-810. PubMed ID: 16375608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
    Schaber JD; Fang H; Xu J; Grimley PM; Rui H
    Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells.
    Zitzmann K; Brand S; De Toni EN; Baehs S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
    Cancer Res; 2007 May; 67(10):5025-32. PubMed ID: 17510435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents.
    Li Q; Kawamura K; Ma G; Iwata F; Numasaki M; Suzuki N; Shimada H; Tagawa M
    Eur J Cancer; 2010 Jan; 46(1):180-90. PubMed ID: 19879751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I interferons impair BDNF-induced cell signaling and neurotrophic activity in differentiated human SH-SY5Y neuroblastoma cells and mouse primary cortical neurons.
    Dedoni S; Olianas MC; Ingianni A; Onali P
    J Neurochem; 2012 Jul; 122(1):58-71. PubMed ID: 22533963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.
    Vitale G; van Eijck CH; van Koetsveld Ing PM; Erdmann JI; Speel EJ; van der Wansem Ing K; Mooij DM; Colao A; Lombardi G; Croze E; Lamberts SW; Hofland LJ
    Ann Surg; 2007 Aug; 246(2):259-68. PubMed ID: 17667505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro and In Vivo Preclinical Effects of Type I IFNs on Gliomas.
    Galani V; Papadatos SS; Alexiou G; Galani A; Kyritsis AP
    J Interferon Cytokine Res; 2017 Apr; 37(4):139-146. PubMed ID: 28387596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.